CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: a randomized phase II study of the AGO
M Möhler, J Siebler, T Höhler, J Janssen, A Wein, M Menges, D Flieger, T Junginger, PR Galle, M Heike · Zeitschrift für Gastroenterologie · 2004 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Combinations of irinotecan (CPT11) with continuous folinic acid (FA) and 5-fluorouracil (5-FU) have shown promising activity in advanced or metastatic gastric cancer (AGC). We prospectively evaluated toxicity, efficacy and survival of CPT11/FA/5-FU (arm A) versus Etoposide/FA/5-FU (ELF; arm B) in AGC. As ELF was not inferior to FAMTX or Cisplatin/5-FU in a recent EORTC trial, ELF served as control arm. Methods: Metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction; performance status (PS) 0–2; no prior chemotherapy. Patients (pts) were eligible and randomized to arm A wi…
